Inhibitory Effect of Phosphorothioate Oligonucleotide Complementary to G6PD mRNA on Murine Melanoma

Abstract

In terms of the incidence among all tumors, skin cancer is on top, with the most deadly among them being melanoma. The search for new therapeutic agents to combat melanoma is very relevant. In our opinion, antisense oligonucleotides (ASO) aimed at suppressing the genes responsible for their viability in cancer cells give hope for treatment, which makes it possible to eliminate cancer cells near the tumor site both before and after surgery. In this article, we describe how Skeen-11 phosphorothioate oligonucleotide significantly decreased the proliferative activity of murine melanoma cells. Injections of Skeen-11 also inhibited tumor growth in mice with inoculated melanoma. A toxicity study showed no side effects with dose adjustments. The results show that the use of ASO Skeen-11 in vivo reduced the tumor size within 7 days, reduced the number of mitoses in the tumor cells, and increased the amount of necrosis compared with the control group.

Current Progress in Vaccines against Merkel Cell Carcinoma: A Narrative Review and Update

“…Other therapeutic approaches currently focus on the energy metabolism, such as glycolysis and enhanced glucose uptake, as well as decreased oxidative metabolism. Energy metabolism is altered in many cancers and may be addressed with the use of antisense oligonucleotides or GAPDH-inhibitors such as fumaric acid esters [33,57,58].…”